AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02237391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIPAP Program
Description: The intervention will involve a pain specialist, a clinical health psychologist and a nurse. As needed, it may involve a social worker, an addiction specialist, and other specialists. The pain specialist will conduct an evaluation that includes: history of presenting illness, review of systems, review of pain treatments, medical history, surgical history, addiction history, medications and allergies, insurance for medication, psychosocial history, opioid risk assessment, physical examination, and review of tests and investigations. The psychologist will conduct an evaluation that includes: a structured diagnostic clinical interview, a review of coping strategies, and a review of the questionnaires completed prior to the assessment pertaining to mood, anxiety, trauma and beliefs about pain.
Study NCT02237391 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual (TAU)
Description: Control group
Study NCT00738348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sivelstat
Description: sivelstat sodiumhydrate
Study NCT00738348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: glucose
Description: glucose
Study NCT00388726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389
Description: 1.4 mg/m\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.
Study NCT01724450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: 50mg/day for 24 weeks. The dose of carvedilol will be up titrate before the dose of 50mg/day
Study NCT01724450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo similar to the carvedilol up titration but wit no active drug.
Study NCT05449860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation using combined bipolar and monopolar energy deliver with Twin Cooled-Wet electrodes
Description: Radiofrequency ablation will be performed by using twin cooled-wet electrodes. Two electrodes will be places on the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF, bipolar mode and switching monopolar mode) will be applied to two electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C. The RF energy will be delivered by using the 200 watts single generator.
Study NCT01261923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alitretinoin
Description: 30 mg capsule of 9-cis-retinoic-acid (9-cis-RA)(Alitretinoin, Toctino®)
Study NCT02968277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Rollator
Description: A control rollator device
Study NCT02104115 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI scanners
Study NCT02104115 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: VAS Symptom scores
Study NCT03148665 — intervention group
Intervention type: DEVICE
Intervention: OncAlert
Description: A noninvasive point of care salivary rinse test performed as 1) a one-time test for control subjects, 2) at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients
Study NCT01128179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Description: 1000 mg in chewable tablets administered three times a day (for a total of 3000 mg/day) for 12 weeks
Study NCT01128179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo chewable tablets administered 3 times a day for 12 weeks
Study NCT00520897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir (MK0518)
Description: 400mg BID; 48 weeks
Study NCT00520897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400mg QD
Study NCT00520897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukopheresis
Description: pack of cells as per protocol
Study NCT00520897 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Leukopheresis
Description: pack of cells as per protocol
Study NCT00520897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoid Biopsy
Description: gut samples as per protocol
Study NCT00997399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat (LBH589)
Study NCT02611141 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Retromolar laryngoscopy and scoring of the visualisation of the vocal cords according to Cormack & Lehane
Description: To facilitate the insertion of the straight blade laryngoscope (Miller #4) the head of the patient will be turned to the left side. The blade will be inserted and then pushed laterally rightwards until the retromolar space will be finally reached. Thereafter the epiglottis will be lifted up in order to achieve the best direct view to the vocal cords and scored according to Cormack \& Lehane .~This score will be assessed at least 2 minutes after muscle relaxation:~1. Once without a backward, upward, rightwards pressure maneuver (=BURB) and immediately thereafter (i.e. 5-10 seconds later):~2. If 100% visualization of the vocal cords is not possible a BURP maneuver will be performed and the scored again.~Intubation will then be performed by the conventional method using a Macintosh blade #3. In the case that intubation with the conventional method is not successful the retromolar technique will be used.
Study NCT00702455 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Directed (weight loss maintenance)
Description: Self- Directed participants will receive a core set of print materials describing key behaviors and skills necessary for successful weight loss maintenance and will review these materials with an intervention coach in two sessions.
Study NCT01138605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
Study NCT01138605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Liquid formulation, 80 mg/ml, taken in combination with Darunavir
Study NCT01138605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
Study NCT01138605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Oral suspension 100 mg/ml, 20 mg/kg twice daily in combination with ritonavir for body weight between 10 and 20 kg
Study NCT01138605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
Study NCT01138605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
Study NCT01138605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
Study NCT01138605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 400 mg tablet, intake of 2 tablets once daily in combination with ritonavir
Study NCT01138605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir powder for oral suspension 10 mg/mL taken in combination with Darunavir.
Study NCT00320619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epsilon-Aminocaproic Acid (EACA)
Description: Participants will receive EACA intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
Study NCT00320619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
Study NCT02498340 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: non- fava beans
Description: Patients will be subjected to eat non- fava beans diet at doses of 10 -30 gm (small to moderate amount) of 3 different types of non- fava beans, each one will be given once daily for 3 days.
Study NCT01063699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Kasai operation
Description: the Kasai procedure (hepatoportoenterostomy) is performed laparoscopically, thus not in open surgery.
Study NCT04184752 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic study
Description: The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position \[14\]. A 20-minute pad test for each woman was also performed \[15, 16\]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS \[3\]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
Study NCT01083615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: custirsen sodium
Description: An antisense oligonucleotide that blocks production of clusterin
Study NCT01083615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic, 0.9% sodium chloride
Description: Placebo for custirsen sodium
Study NCT01083615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT01083615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: docetaxel
Study NCT01083615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel
Study NCT01083615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cabazitaxel
Study NCT01083615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT01083615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisone
Study NCT00902473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: 25mg tablets
Study NCT00902473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: 25mg tablets
Study NCT04411472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human alkaline phosphatase
Description: patients with SA-AKI are randomly assigned in a 1:1 ratio to either placebo or 1.6 mg/kg recAP.
Study NCT04411472 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02532998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 oral suspension
Description: AZD9977 oral suspension, single dose
Study NCT02532998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 placebo oral suspension
Description: oral suspension, single dose
Study NCT02532998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone, tablets
Description: Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)
Study NCT02532998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone, tablets
Description: 100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)
Study NCT03331939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no stimulation
Description: Vagal nerve stimulator will be set to no stimulation
Study NCT03331939 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: beta (25-30 Hz)
Description: Vagal nerve stimulator will be set to beta (25-30 Hz)
Study NCT03331939 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Theta (5 Hz)
Description: Vagal nerve stimulator will be set to beta (5 Hz)
Study NCT00702455 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided (weight loss maintenance)
Description: Guided participants will receive 8 monthly check in calls and then bimonthly calls for the rest of the study. Guided participants are also asked to report their weight weekly, either via the Keep It Off website, email or voicemail. Those who experience weight gain will receive outreach calls to assist them in reversing their weight gain.
Study NCT01016314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspen Spinous Process System
Description: Aspen Spinous Process System is an interspinous process fixation device
Study NCT01016314 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pedicle Screw Fixation
Description: Pedicle Screws are used for the fixation of the spine
Study NCT01968577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 40 mg before percutaneous coronary intervention
Study NCT04172961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanomicellular cyclosporine 0.09%
Description: topical ophthalmic drop prior to elective surgery for eligible patients
Study NCT04172961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lifitegrast
Description: topical ophthalmic drop prior to elective surgery for eligible patients
Study NCT03622177 — intervention group
Intervention type: PROCEDURE
Intervention: biopsie
Description: Additional colorectal mucosal biopsies during rectoscopy or colonoscopy
Study NCT03622177 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood drawn
Description: Additional blood drawn by venepuncture
Study NCT00520897 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sigmoid Biopsy
Description: gut samples as per protocol
Study NCT01969500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application
Study NCT01969500 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Study NCT02639338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: 400/100/100 mg FDC tablet administered orally once daily with food
Study NCT02639338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily without regard to food
Study NCT02428920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Groups
Description: The intervention group arm will attend biweekly or monthly peer group meetings to discuss health successes and challenges.
Study NCT01893359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riboflavin ophthalmic solution, 0% dextran
Study NCT01893359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA)
Study NCT01893359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off)
Study NCT01893359 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Laser-assisted in situ keratomileusis
Study NCT01893359 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser-assisted in situ keratomileusis
Study NCT03838497 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13
Description: Prevenar13 for both arms
Study NCT04271917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol
Description: Use of cannabidiol as an alternative to standard of care treatment of acute pain.
Study NCT04271917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Inactive placebo oil to imitate CBD oil
Study NCT04271917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen 500mg and ibuprofen 200mg combo
Description: standard of care
Study NCT02303821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Study NCT02303821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02303821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Study NCT02303821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase
Study NCT01341626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Foster Care (TFCO)
Description: Youth placed individually in well-trained and supervised foster homes. Basic components: (a) daily telephone contact with TFCO parents; (b) weekly foster parent group meetings focused on supervision, training in parenting practices, and support; (c) an individualized behavior management program implemented daily in the home by foster parent; (d) individualized skills training for the youth; (e) family therapy for aftercare family focused on parent management strategies; (f) close monitoring of school attendance, performance, and homework completion; (g) case management to coordinate TFCO, family, peer, and school settings; (h) 24-hour on-call staff availability to TFCO and biological parents; and (i) psychiatric consultation. Services typically last approximately 6 months.
Study NCT01341626 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Care
Description: Group Care is the usual service for youth placed in out-of-home care for chronic delinquency in Oregon. These programs represented typical services for girls being referred to out-of-home care by the juvenile justice system and had 2-51 youth in residence (M = 21) and 1-50 staff members (Mdn = 2); most also had onsite schooling. Although the programs differed somewhat in theoretical orientations, 86% reported that they endorsed a specific treatment model, of which the primary philosophy was a behavioral (70%), eclectic (26%), or family-style therapeutic approach (4%). Services typically last approximately 6 months.
Study NCT03167489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Plus Emotional Regulation
Description: Group intervention over 5 months, integrating the Mediterranean Diet into a lifestyle intervention and emotional regulation skills.
Study NCT01634529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V158866
Description: Single ascending oral doses of V158866 and Placebo
Study NCT01634529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V158866
Description: Multiple ascending oral doses of V158866 and Placebo
Study NCT01367392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biopsy or ablation
Description: biopsy or ablation performed as in standard of care with assistance of ActiSight Needle Guidance system
Study NCT02570243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of Unfractionated Heparin
Description: Unfractionated Heparin 100IU/Kg
Study NCT02570243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose of Unfractionated heparin
Description: Unfractionated heparin 50IU/Kg
Study NCT03541187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: German cockroach allergenic extract
Description: Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467).
Study NCT03541187 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for German cockroach allergenic extract
Description: Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%).
Study NCT00961792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Beverage containing 0.8 g/kg ethanol, 0.4 g/kg ethanol
Study NCT00961792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Beverage containing 0.0 g/kg alcohol to act as placebo
Study NCT00961792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Beverage containing dose equivalent to 1.5 standard doses of Diphenhydramine (Benadryl)
Study NCT00961792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Beverage containing the equivalent of 1.5 times the participant's daily caffeine intake
Study NCT04024904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OncomfortTM device
Description: The VHRD (Virtual Reality Hypnosis Distraction) technique is the program of OncomfortTM (Oncomfort Inc, Houston, USA). The OncomfortTM device include the hyper vision 3D virtual reality glasses and disposable single-patient-use headphones. The program is an immersive experience focused on inducing relaxation environment and this program exist in 5,15 and 30 minutes
Study NCT00299013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
Study NCT03349866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: apatinib：250mg qd po
Study NCT03349866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000mg/m2 bid d1-14